TO DA MOON
We all heard it.
This stock is going TO DA MOON.
Some stocks do go TO DA MOON and I”m holding 3 that have the potential to go TO DA MOON. These stocks are my trifecta play.
I’m hopeful that they all go To DA MOON.
What is very interesting is that these stocks have many similarities.
All are biotechs.
All have a potential Covid-19 solution.
All have a potential cancer solution.
All are OTC stocks.
The best companies deliver the most shareholder value by creating a product that radically changes the face of medicine. Amgen revolutionized patient care in chemotherapy. Celgene addressed tough diseases with its own discoveries. In 2021, we're seeing the fruits of messenger RNA technology leading to the rapid development of Covid-19 vaccines.
All 3 of these companies have the potential to radically change the face of medicine.
Biotechnology is a sector where traders seek out these huge profits. For smart traders, this sector can present an incredible area of opportunity, but for those who are not willing to do their homework, it can be a train wreck waiting to happen.
Have you done your homework?
Is SBFM one of my trifectas?
Why of course it is.
Some of you are holding the other 2 which suggest some serious DD has been going on.
Few sectors in the market see small single-product companies go from having tiny market capitalizations to having a worth over hundreds of millions practically overnight. The business of curing diseases can be a lucrative one, and investors will jump on the bandwagon for any stock that shows the promise of a big breakthrough.
Key Stock Catalysts in the FDA Drug Application Process
Drug development in the US follows a standard process through which pharmaceutical and biotech companies advance a new drug candidate through nonclinical and clinical studies.
Once the company’s clinical data proves the drug is safe and effective, they can apply for market approval from the Food and Drug Administration (FDA). This is known as the FDA drug approval process.
As a drug candidate moves through each stage of the FDA regulatory approval pathway, there are several catalysts along the way that can represent significant value drivers for the company’s stock price. Tracking these inflection points can prove helpful to investors looking for opportunities in this space.
FDA drug approval pathway
Preclinical studies—animal models; safety profile
Investigational New Drug Application to conduct human trials submitted to FDA
Phase 1 Clinical Trial—safety profile, dosage
Phase 2a and 2b Clinical Trials—safety and efficacy
Phase 3 Clinical Trials—Pivotal large-scale studies to acquire data for FDA approval
New Drug Application for marketing product submitted to FDA
AdCom meetings—expert independent panelists review
PDUFA date—FDA decision on approving a drug for market
Traditionally, pharmaceutical product development companies must first perform preclinical work with animals to establish that the drug is safe before applying to conduct human clinical studies. The company can then submit an Investigational New Drug (IND) application to the FDA. Once the FDA has greenlighted human studies, the drug then must pass through three phases of clinical trials in which the company must obtain sufficient data to prove safety and efficacy.
At the conclusion of each clinical phase, the data is submitted to the FDA. The regulatory body will then make a decision as to whether or not the drug is a viable candidate for the next clinical phase. The completion of Phase 3 data moves the drug candidate to the final stage of the approval process, the Prescription Drug User Fee Act (PDUFA) meeting date.
Inflection points represent investment opportunities
Companies looking to raise capital often update investors as to the status of their drug candidates along the pathway to FDA market approval. A news release featuring great clinical study readouts can be the catalyst that triggers significant upward movement in the company’s share price. It’s these inflection points that really move a pharma or biotech stock.
So, which stages in the FDA approval process are likely to be the biggest drivers of shareholder value?
Positive early stage results offer some value
“As you advance your product through each of these steps, the product becomes de-risked in the eyes of investors,” Bob Farrell, president and CEO of Kalytera Therapeutics (TSXV:KALY,OTCQB:KALTF), told INN. “For example, when you complete preclinical studies, you have demonstrated that the product is safe enough in animals that it can now be tested in humans. Typically, you see a small bump up in share price at that time.”
Phase 1 human clinical testing, in which safety and proper dosage are studied, can be another inflection point for upward pressure on the stock. Positive Phase 1 data further de-risks a product by signaling the drug is ready for larger-scale testing.
However, Farrell—who has more than 25 years of experience in the pharmaceutical, biotechnology and medical device sectors—says the more substantial inflection points come later as the drug progress through the final phases. “As you move toward the final goal of approval, it’s like moving up a staircase with each step representing the potential for a higher valuation and ultimately a higher share price,” he added.
Later-stage clinical results represent the sweet spot
The most significant value driving events are the conclusion of Phase 2 and Phase 3 clinical trials. This is where the real de-risking happens and the drug developer moves one step closer to submitting the new drug application (NDA) to the FDA for final market approval. Strong Phase 2 and Phase 3 data give investors confidence that the drug will receive that approval.
“Important trial data from Phase 2 and Phase 3 studies can produce extraordinary trading volume and price movement,” said George Mack, Managing Director of consulting firm BioDecade. “Trial results that tend to move shares are those that yield statistically significant data, which can only be derived from the randomized, double-blind experiments performed in Phase 2b and Phase 3 trials.”
Phase 3 testing typically involves large clinical trials that can be very expensive to conduct. It is not uncommon for small biotech firms to sell a Phase 2 product or license it to a big pharmaceutical company instead of advancing the product through Phase 3 themselves.
Final stage inflection points
Phase 3 data forms the basis for a company’s NDA in which it formally seeks final market approval from the FDA. Once a drug developer submits the application, the FDA will announce the PDUFA meeting date—the day the regulatory body with give its final decision to approve or not approve the new drug. In the lead up to the PDUFA date, the FDA may hold Advisory Committee (AdCom) meetings in which independent panelists give yay or nay expert opinions on whether the FDA should allow the drug to go to market.
The submission of the NDA, AdComs and the FDA’s announcement of the PDUFA date represent the final steps in the regulatory pathway. News releases on these critical milestones can make quite an impression on investors and a significant impact on share prices.
https://investingnews.com/daily/life-science-investing/biotech-investing/tracking-key-stock-catalysts-in-the-fda-drug-approval-process/
As the above information suggests, it will take time for new drugs to go through the regulatory process so PATIENCE is necessary.
It really is exciting to have 3 Biotechs that all of which possess technology that can have a tremendous impact on humanity.
